ERBB2 and breast carcinoma: Although HER4 expression has been shown to improve trastuzumab response [20, 21], there has been no detailed report on how trastuzumab affects HER4 expression, activation and cleavage and how these processes mediate sensitivity and resistance to trastuzumab in HER2 positive breast cancer cells.